These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 487647)

  • 1. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Jun; 36(3):456-64. PubMed ID: 487647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Jan; 35(1):36-44. PubMed ID: 428146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
    Thatcher N; Crowther D
    Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 May; 36(2):227-36. PubMed ID: 314367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Feb; 35(2):171-9. PubMed ID: 312169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with bacterial ribosomal antigens in bronchial asthma. II. Immunological study.
    Subirá ML; Oehling A; Diéguez I; Martín-Gil D
    Allergol Immunopathol (Madr); 1982; 10(1):53-60. PubMed ID: 7080995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of diphenylhydantoin on killer cell activity and other immunological functions. A sequential study including the interaction of Corynebacterium parvum in melanoma patients.
    Thatcher N; Wan HH; Swindell R; Wilkinson PM; Crowther D
    Int J Immunopharmacol; 1982; 4(3):167-74. PubMed ID: 7107099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the rosette forming capacity of lymphocytes after surgery or surgery and immunochemotherapy of malignant melanoma in man.
    Hadjikirova M; Boeva M; Ikonopisov R
    Biomed Pharmacother; 1982; 36(5):257-9. PubMed ID: 7168802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-T antibody in malignant melanoma patients. Influence of response and survival following chemotherapy--changes in serum levels following C parvum, BCG immunization.
    Thatcher N; Hashmi K; Chang J; Swindell R; Crowther D
    Cancer; 1980 Sep; 46(6):1378-82. PubMed ID: 7417939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immune profile in melanoma patients. I. PHA--stimulation of circulating lymphocytes and number of T- and B-lymphocytes (author's transl)].
    Knopf B; Wätzig V; Knöll B
    Arch Geschwulstforsch; 1978; 48(6):559-64. PubMed ID: 310289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of Corynebacterium parvum on the humoral and cellular immune systems in patients with breast cancer.
    Minton JP; Rossio JL; Dixon B; Dodd MC
    Clin Exp Immunol; 1976 Jun; 24(3):441-7. PubMed ID: 1084821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Corynebacterium parvum on cellular immunity of cancer patients, assayed sequentially over 63 days.
    Thatcher N; Lamb B; Swindell R; Crowther D
    Cancer; 1981 Jan; 47(2):285-90. PubMed ID: 7459817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative antitumor effects of Corynebacterium parvum, Bordetella pertussis, Bacillus Calmette-Guérin, and levamisole alone or in combination with cyclophosphamide in the CaD2 murine mammary adenocarcinoma system.
    Purnell DM; Bartlett GL; Kreider JW; Biro TG; Kontra J
    Cancer Res; 1979 Dec; 39(12):4838-42. PubMed ID: 498111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of Corynebacterium parvum therapy on immunoglobulin class and IgG subclass levels in cancer patients.
    James K; Clunie GJ; Woodruff MF; McBride WH; Stimson WH; Drew R; Catty D
    Br J Cancer; 1975 Sep; 32(3):310-22. PubMed ID: 61040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inefficacy of sc Corynebacterium parvum in stage I malignant melanoma: preliminary results of a single-institution pilot study.
    Murray JL; Ishmael DR; Bottomley RH; Grozea PN; Lee ET
    Cancer Treat Rep; 1983 Feb; 67(2):191-2. PubMed ID: 6825130
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of BCG and C. parvum treatment on human melanoma xenografts.
    Garrett AJ; Reeson DE; Osborn TW; Boulger LR
    Dev Biol Stand; 1977 Apr 13-15; 38():363-8. PubMed ID: 608525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulation by Corynebacterium parvum in normal humans.
    Hokland P; Ellegaard J; Heron I
    J Immunol; 1980 May; 124(5):2180-5. PubMed ID: 6154095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged BCG treatment of melanoma: does it suppress the immune capacity?
    Helander I; Nordman E; Häkkinen IP; Toivanen A
    Br J Dermatol; 1979 Oct; 101(4):421-7. PubMed ID: 508607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immune profil in melanoma patients. III. Behavior of immunglobulins (IgG, IgA, IgM) and of whole complement in serum at the beginning and during BCG-therapy (author's transl)].
    Knopf B; Wätzig V; Stelzner A
    Arch Geschwulstforsch; 1979; 49(4):299-304. PubMed ID: 496567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.